{
    "clinical_study": {
        "@rank": "151366", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "100 mg PF-05231023", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a trial in obese subjects to study the safety, tolerability, pharmacokinetics and\n      pharmacodynamics of multiple doses of PF-05231023."
        }, 
        "brief_title": "Multiple Dose Study Of PF-05231023 In Obese Adult Subjects", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus (T2DM)", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects of non-childbearing potential between the ages of 21 and 70.\n\n          -  Subjects with a BMI of 30 to 45.4 kg/m2 and total body weight >110 lbs.\n\n        Exclusion Criteria:\n\n          -  Recent (6 months) unstable concurrent disease.\n\n          -  History of allergic disease or drug allergies.\n\n          -  Any condition affecting food consumption or absorption."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "4", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01923389", 
            "org_study_id": "B2901009"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "100 mg PF-05231023", 
                "description": "100 mg IV infusion twice a week for 4 weeks", 
                "intervention_name": "100 mg PF-05231023", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "T2DM", 
            "obesity", 
            "safety", 
            "multiple dose", 
            "intravenous"
        ], 
        "lastchanged_date": "March 18, 2014", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2901009&StudyName=Multiple%20Dose%20Study%20Of%20PF-05231023%20In%20Obese%20Adult%20Subjects"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32804"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32803"
                    }, 
                    "name": "Pfizer Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Placebo-Controlled, Randomized Trial To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenous Doses Of PF-05231023 In Obese Adult Subjects", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence and severity of all causality Adverse Events and treatment-emergent Adverse Events, ECG parameters, SBP, DBP, Pulse Rate, Laboratory trends and incidence of abnormalities per Sponsor's safety reporting standards.", 
                "safety_issue": "No", 
                "time_frame": "68 Days"
            }, 
            {
                "measure": "Anti-PF-05231023 antibodies and neutralizing antibodies", 
                "safety_issue": "No", 
                "time_frame": "68 Days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01923389"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PK of PF-05231023 after multiple intravenous doses including Cmax and Cmin", 
                "safety_issue": "No", 
                "time_frame": "68 Days"
            }, 
            {
                "measure": "PK of sub-components of PF-05231023 including AUCtau, Cmax, Tmax after a single dose and  accumulation ratio (AUC and Cmax), Cmin and Cav after the last dose", 
                "safety_issue": "No", 
                "time_frame": "68 Days"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014", 
        "why_stopped": "The study was terminated on December 19th, 2013 due to a business decision by the Sponsor.  No\n    safety concerns have been observed in this study."
    }
}